

Valeant Pharmaceuticals International, Inc.  
Form 8-K  
March 09, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of the earliest event reported): March 9, 2015 (March 9, 2015)**

**Valeant Pharmaceuticals International, Inc.**

**(Exact name of registrant as specified in its charter)**

**British Columbia, Canada**  
**(State or other jurisdiction of**  
**incorporation or organization)**

**001-14956**  
**(Commission**  
**File Number)**  
**2150 St. Elzéar Blvd. West**

**98-0448205**  
**(I.R.S Employer**  
**Identification No.)**

Edgar Filing: Valeant Pharmaceuticals International, Inc. - Form 8-K

**Laval, Quebec**

**Canada H7L 4A8**

**(Address of principal executive offices) (Zip Code)**

**(Registrant's telephone number, including area code): (514) 744-6792**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure**

In connection with its proposed acquisition of Salix Pharmaceuticals, Ltd., Valeant Pharmaceuticals International, Inc. (the Company) intends to enter into certain financing transactions (the Financing Transactions). In connection with the Financing Transactions, a meeting is scheduled between senior officers of the Company and its lenders to be held on March 9, 2015. In connection with these efforts, the Company will be making a slide presentation to prospective lenders (the Lender Presentation Slides). Certain of the Lender Presentation Slides are furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01 and Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

**Exhibit**

<b>Number</b>	<b>Description</b>
99.1	Lender Presentation Slides.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VALEANT PHARMACEUTICALS  
INTERNATIONAL, INC.

Date: March 9, 2015

By: /s/ Howard B. Schiller  
Howard B. Schiller

Executive Vice President, Chief Financial Officer

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Lender Presentation Slides.